NCT05857943CompletedNot Applicable
Prospective Clinical Trial to Demonstrate the Efficacy and Safety if AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images Obtained With a Funduscopic Device
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AEYE Health Inc
- Enrollment
- 363
- Locations
- 3
- Primary Endpoint
- Sensitivity and Specificity
Study Overview
Brief Summary
AEYE-DS is a software device developed to increase compliance with diabetic retinopathy screening by automatically detecting more-than-mild diabetic retinopathy from digital funduscopic images using AI-based software. This study has been designed to validate the safety and efficacy of the device at primary care and other point of care sites.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 22 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female
- •Documented diagnosis of diabetes mellitus, meeting the criteria established by the American Diabetes Association (ADA) and World Health Organization (WHO):
- •Understand the study and volunteer to sign the informed consent
Exclusion Criteria
- •Uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters.
- •Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion.
- •Previously diagnosed with Diabetic Retinopathy.
- •History of laser treatment of the retina or injections into either eye, or any history of retinal surgery.
- •Currently participating in another investigational eye study and actively receiving investigational product for DR or DME.
- •Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation).
- •Participant is contraindicated for imaging by fundus imaging systems used in the study:
- •Participant is hypersensitive to light
- •Participant recently underwent photodynamic therapy (PDT)
- •Participant is taking medication that causes photosensitivity
- •Participant has a history of angle-closure glaucoma or narrow anterior chamber angles
- •Subject is pregnant.
Arms & Interventions
AEYE-DS Software Device
Experimental
An AI software device (AEYE-DS) to be used as a diagnostic tool to assist primary care clinicians in screening for diabetic retinopathy using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy
Intervention: AEYE-DS Software (Device)
Outcomes
Primary Outcomes
Sensitivity and Specificity
Time Frame: 1 year
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Not Applicable
Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus ImagesDiabetes MellitusDiabetic RetinopathyNCT04612868AEYE Health Inc531
Completed
Not Applicable
Efficacy and Safety of AEYE Diagnostic Screening (AEYE-DS) Software Device for Detection of Diabetic Retinopathy From Digital Funduscopic ImagesDiabetic Retinopathy, DRDiabetic MellitusNCT06241664AEYE Health Inc601
Completed
Not Applicable
Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine ClinicDiabetes MellitusNCT03828890Mayo Clinic36
Active, not recruiting
Not Applicable
Diabetic Retinopathy Screening Point-of-Care Artificial IntelligenceDiabetic Retinopathy (DR)NCT06721351Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health548
Unknown
Not Applicable
Implementation of an Integrated System of Artificial Intelligence and Referral Tracking for Real-time Diabetic Retinopathy ScreeningScreeningArtificial IntelligenceDiabetic RetinopathyNCT05166122Rajavithi Hospital1,600